anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Table

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 60,557
Current window 26,581-26,610
Pages 2,019
Rows per page 30
Component: Tableclear collectionreset all
18 30 60

Component

26,581-26,610 of 60,557

filter-aware
312
The slide uses a red box to highlight the company's claim, contrasting it with the activist's observation that no activity is visible.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 1 hit
06
The slide uses aggressive, highly critical language to frame the upcoming sections of the report.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
07
This is a continuation of a larger table of contents, starting at item 13.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
08
This slide appears to be a continuation of a larger table of contents, starting at page 18.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
12
The slide uses a strong, accusatory tone, labeling the company a 'textbook Ponzi'.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The MonsterLoop · The Reveal1 hit
14
The slide highlights Nevro's underperformance compared to its peers in the top 50 medtech companies by market cap.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The MonsterLoop · The Reveal1 hit
85
The slide uses a screenshot of a medical journal article to highlight author conflicts of interest and a table of explant data to challenge the company's claims.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Victory1 hit
86
The slide uses a red circle to highlight a specific table from a medical paper, emphasizing the discrepancy between real-world outcomes and company claims.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Victory1 hit
148
Uses a combination of internal research claims and external clinical literature to expose a contradiction in the company's product claims.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller Beat · The Victory1 hit
05
QuantumScape (QS)QuantumScape (QS) · Scorpion Capital
Activist deck Short seller 1 hit
06
QuantumScape (QS)QuantumScape (QS) · Scorpion Capital
Activist deck Short seller 1 hit
16
Uses a precedent (INFN) to predict a negative outcome for the target (QS).QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
29
The slide uses a table to demonstrate 'cherry-picking' by showing that key variables like prototype size and temperature are not held constant across tests.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
94
Includes a screenshot of a competitor's slide and a reference table for C-rates.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
125
The slide uses a red box to draw attention to the specific text in the source document.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
173
The slide uses a 'before-after' style comparison to frame Quantumscape as a repeat of the Sakti3 fraud.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
181
Uses historical precedent (Infinera) to cast doubt on current QS insiders; includes red dashed circles highlighting zero-balance positions.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
183
The slide uses red boxes and arrows to draw attention to specific, aggressive growth figures in the financial table.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
21
The slide uses a direct quote from the Pediatric Endocrine Society guidelines to expose the company's failure to address known side effects in their trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
38
The slide uses an excerpt from the FDA label to critique the clinical trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
107
The slide uses red boxes to draw attention to the specific data points being compared.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
184
The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
198
The slide lists four specific US patents to support the claim of weakness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit